Identification of Risk Factors for Atrial Fibrillation After Ablation of an Atrial Flutter by Radiofrequency of the Cavotricuspid Isthmus.
NCT ID: NCT03919097
Last Updated: 2022-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2019-01-08
2019-11-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Several studies have been published concerning the factors associated with the occurrence of atrial fibrillation during or after flutter ablation, in patients with and without clinical history of atrial fibrillation. 26 to 46% of patients are likely to develop it, according to ECG or Holter diagnoses. The figure rises to more than 50% with a diagnosis with an implantable loop recorder.
In patients without a prior history of atrial fibrillation before ablation, anticoagulants are routinely administered 4-6 weeks after flutter removal by most cardiologists.
Although there are no specific guidelines for anticoagulation after flutter ablation, it is currently recommended to treat the patient as for atrial fibrillation. It is therefore crucial to identify in advance patients at high risk of atrial fibrillation after flutter ablation, in order to assess the appropriateness of maintaining oral anticoagulant therapy.
The objectives of this study are:
* to evaluate the frequency and identify the factors predicting the occurrence of atrial fibrillation after flutter ablation
* to determine the risk of a stroke occurring in patients with atrial fibrillation after flutter ablation.
The database consists in patients of the CHU Brugmann Hospital treated between 1996 and 2018.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Remote Magnetic Navigation For Cavotricuspid Isthmus Ablation
NCT00560872
Therapy of Atrial Flutter by Afib Ablation
NCT02051621
Randomized Study of Radiofrequency- vs. Cryo-Ablation for Typical Isthmus-Dependent Atrial Flutter
NCT00196170
Catheter Ablation as the First Line Therapy for Typical Atrial Flutter
NCT00213408
Cryoballoon Ablation as First Line Treatment of Atrial Flutter
NCT03401099
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
No atrial arrhythmia post-ablation of a flutter by radiofrequency of the isthmus of the cavotricuspid valva.
Medical Data extraction
Data extraction from the patient's Medical Files
Atrial fibrillation post ablation
Atrial arrhythmia (Atrial Fibrillation) post-ablation of a flutter by radiofrequency of the isthmus of the cavotricuspid valva.
Medical Data extraction
Data extraction from the patient's Medical Files
Flutter recidive
Recidive of the flutter after ablation.
Medical Data extraction
Data extraction from the patient's Medical Files
Atrial Fibrillation antecedents
Patients with atrial fibrillation after flutter ablation, with previous antecedents of atrial fibrillation.
Medical Data extraction
Data extraction from the patient's Medical Files
No Atrial Fibrillation antecedents
Patients with atrial fibrillation after flutter ablation, without antecedents of atrial fibrillation.
Medical Data extraction
Data extraction from the patient's Medical Files
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Medical Data extraction
Data extraction from the patient's Medical Files
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
José Castro
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
José Castro
Head of cardiology clinic
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Georges Fayad, MD
Role: PRINCIPAL_INVESTIGATOR
CHU Brugmann
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Brugmann
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHUB-Fayad
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.